Compound with the potential to treat drug-resistant HIV identified

Scientists have discovered a novel compound, IC-2i, that shows strong potential in treating drug-resistant HIV. The research team, comprising experts from various countries, developed this compound by combining and refining parts of previously studied HIV inhibitors. The HIV capsid, the protein shell that protects the virus, was identified as a crucial target for antiviral drugs, as it plays a role in the virus's life cycle.

The new compound, IC-2i, was found to bind to a less mutation-prone region of the HIV capsid, making it effective against some drug-resistant variants. Researchers used the microfocus crystallography (MX2) beamline at the Australian Synchrotron to determine the structure of IC-2i and understand how it binds to its target. This discovery opens up possibilities for designing future HIV medicines that can address resistance issues, which are a major challenge in HIV treatment.

Despite significant advancements in HIV treatment, lifelong therapy is still necessary due to the virus's ability to hide in reservoirs within the body, leading to the need for safer and more effective drugs. The World Health Organization estimates that around 39 million people were living with HIV worldwide at the end of 2022, with 1.3 million new infections and 630,000 deaths reported that year.

While modern combination antiretroviral therapy can effectively control HIV, it cannot eliminate the virus completely. The development of IC-2i represents a significant step forward in the search for better HIV treatments. Further evaluation is needed to establish the safety, stability, and clinical efficacy of this compound.